Calicheamicin Conjugation by Antibody Deglycosylation
    2.
    发明申请
    Calicheamicin Conjugation by Antibody Deglycosylation 审中-公开
    卡利加霉素结合抗体脱糖基化

    公开(公告)号:US20070213511A1

    公开(公告)日:2007-09-13

    申请号:US10592438

    申请日:2005-03-15

    IPC分类号: C07K16/46

    摘要: The present invention provides processed for preparing a calicheamicin conjugate comprising removing glycosylation of a protein and reacting (i) an activated calicheamicin—hydrolyzable linker derivative and (ii) the deglycosylated protein. In one embodiment, the protein is an antibody, such as an anti-CD33 antibody (e.g., hp67.6), an anti-CD22 antibody (e.g., G544), an anti-Lewis Y antibody (e.g., G193), an anti-5T4 antibody (e.g., H8) or an anti-CD20 antibody (e.g., rituximab). In another embodiment, the calicheamicin derivative is an N-acyl derivative of calicheamicin or a disulfide analog of calicheamicin, such as N-acetyl gamma calicheamicin dimethyl hydrazide (N-acetyl calicheamicin DMH) and the hydrolyzable linker is 4-(4-acetylephenoxy) butanoic acid (AcBut) or (3-Acetylphenyl) acetic acid (AcPAc). Also provided are calicheamicin conjugates produced by such processes.

    摘要翻译: 本发明提供加工用于制备加利车霉素缀合物的方法,包括除去蛋白质的糖基化并使(i)活化的加利车霉素可水解连接体衍生物和(ii)去糖基化蛋白质反应。 在一个实施方案中,蛋白质是抗体,例如抗CD33抗体(例如hp67.6),抗CD22抗体(例如G544),抗Lewis Y抗体(例如G193),抗 - -5T4抗体(例如H8)或抗CD20抗体(如利妥昔单抗)。 在另一个实施方案中,加利车霉素衍生物是加利车霉素的N-酰基衍生物或加利车霉素的二硫化物类似物,例如N-乙酰基γ-加利车霉素二甲基酰肼(N-乙酰加利车霉素DMH),可水解接头是4-(4-乙酰基苯氧基) 丁酸(AcBut)或(3-乙酰基苯基)乙酸(AcPAc)。 还提供了通过这些方法生产的加利车霉素缀合物。